Pharma News
19 Oct 2025 to 25 Oct 2025
Oct 25, 2025
Bristol-Myers Squibb Stock Predictions: Analyst Expectations for 2027
Bristol-Myers Squibb (NYSE: BMY) faces challenges with slowing sales and expiring patents, trading near $44/share. Despite this, it reported strong results for its heart failure drug Camzyos and received FDA priority review for Reblozyl in anemia. Analysts project modest upside, with a target of $53/share, while the company maintains a solid cash flow and dividend strategy amid competitive pressures.
Oct 24, 2025
Merck's Q3 Results for Non-Oncology Medications: Anticipations - TradingView
Merck (MRK) is set to report its Q3 2025 results on October 30, with a focus on Keytruda, which comprised over 50% of its pharmaceutical sales in H1 2025. New drugs Capvaxive and Winrevair showed strong sales, while Merck's Animal Health business is also growing. However, competition from companies like United Therapeutics and J&J looms large.
Oct 24, 2025
Eli Lilly's Cancer Medications Set to Shine Before Q3 Earnings Report
Eli Lilly (LLY) is experiencing significant growth in its oncology segment, with projected third-quarter 2025 sales of $2.58 billion, driven by its breast cancer drug Verzenio. Despite competition from other companies like AstraZeneca, Merck, and Pfizer, Lilly's oncology revenues accounted for over 15% of its first-half 2025 sales. The company also recently secured FDA approval for its new drug, Inluriyo.
Oct 24, 2025
Merck's Q3 Results for Non-Oncology Medications: Anticipations Ahead - Yahoo Finance
Merck (MRK) will report its Q3 2025 results on Oct. 30, with a focus on Keytruda, which made up over 50% of its pharmaceutical sales in H1 2025. New drugs Capvaxive and Winrevair showed strong sales, while Merck's Animal Health business is also growing. Competition from United Therapeutics and J&J in PAH, and AstraZeneca/Sanofi in RSV, poses challenges.
Oct 24, 2025
Buyer's club to acquire affordable generic version of expensive Vertex cystic fibrosis medication - STAT News
Families frustrated by the high cost of Vertex Pharmaceuticals' cystic fibrosis treatment, Trikafta, are collaborating with Beximco Pharmaceuticals to create a buyer’s club. The generic version will cost $6,375 for children and $12,750 for adults annually, significantly lower than the U.S. list price exceeding $300,000. Advocacy leader Gayle Pledger hailed this as a historic moment for patient empowerment.
Oct 24, 2025
Dr. Reddy's receives approval to produce generic semaglutide for weight management - The Economic Times
Dr. Reddy's has received approval to manufacture a generic version of semaglutide, a drug used for weight loss. This development is expected to enhance access to effective weight management solutions for patients.
Oct 24, 2025
Sanofi's Stock Rises as Dupixent Revenue Approaches €5 Billion During Heightened Drug Pricing Talks with Trump
Sanofi's shares surged following a strong Q3 2025 report, driven by record sales of its immunology drug, Dupixent, which reached €4.2 billion. The drug's success, co-developed with Regeneron, comes amid the Trump administration's aggressive drug pricing reforms, including the Most-Favored-Nation policy. Analysts maintain a "Buy" rating for Sanofi, highlighting its strategic position in a changing regulatory landscape.
Oct 24, 2025
Merck's Q3 Results for Non-Oncology Medications: Anticipations Ahead - The Globe and Mail
Merck (MRK) is set to report its Q3 2025 results on October 30, with a focus on Keytruda, which contributed over 50% of its pharmaceutical sales in H1 2025. New drugs Capvaxive and Winrevair also showed strong sales. However, competition from United Therapeutics and Johnson & Johnson in the PAH market poses challenges. Merck's stock has declined 12.3% year-to-date.
Oct 24, 2025
Novo Nordisk's newly appointed chairman has full authority following a board overhaul.
Novo Nordisk's boardroom shake-up has granted unprecedented power to its top shareholder, the Novo Nordisk Foundation, which now controls over 77% of voting shares. The foundation's chair, Lars Rebien Sorensen, will also serve as board chairman, raising governance concerns. This change follows declining sales of the obesity drug Wegovy and intensified competition from Eli Lilly, prompting a restructuring plan under CEO Mike Doustdar.
Oct 24, 2025
Dr. Reddy's Laboratories in India falls short of quarterly profit expectations due to intense competition in the generic cancer medication market.
Dr Reddy's Laboratories reported a second-quarter profit of 13.47 billion rupees ($153.25 million), falling short of analysts' expectations of 14.1 billion rupees. The decline was attributed to intense competition for its generic version of the cancer drug Revlimid in the North American market.
Oct 24, 2025
Utilizing Artificial Intelligence in Pharmaceutical Development: The Competition to Innovate and Regulate
AI is revolutionizing drug discovery, with China leading in AI-driven patents and the US facing structural challenges. India has the opportunity to leverage its talent and data to enhance pharmaceutical innovation. Companies like Eli Lilly, Novartis, and Aurigene are integrating AI to streamline drug development. However, India must establish regulatory frameworks to ensure ethical and effective AI applications in healthcare.
Oct 24, 2025
TrumpRx and a favored nation policy are unlikely to reduce costs for patients - STAT News
President Trump signed an executive order for a "most-favored nation" policy aimed at lowering U.S. drug prices, alongside a deal with Pfizer and the launch of the "TrumpRx" website. However, experts argue these measures won't yield significant savings, as pharmaceutical companies exploit patent loopholes, delaying generic drug entry and maintaining high prices for Americans.
Oct 24, 2025
Government plans to revise regulations concerning liquid antiseptics listed in Schedule K, according to Drugs Control Media Services.
The Union Ministry of Health and Family Welfare has proposed a draft amendment to the Drugs Rules, 1945, exempting household liquid antiseptics from sale licenses and hospital-grade antiseptics from retail sale licenses under Schedule K. This change aims to streamline regulations for antiseptic products.
Oct 24, 2025
Supporters and patient organizations establish a collective purchasing group for a generic medication for cystic fibrosis.
At the North American Cystic Fibrosis Conference, non-profit groups launched a community-run buyers' club for a new generic cystic fibrosis treatment, Triko, developed by Bangladeshi company Beximco. Priced at $12,775 annually for adults, it is 96% cheaper than Vertex's Trikafta. Beximco also introduced BexDeco, a generic ivacaftor. The initiative aims to improve access to lifesaving treatments globally.
Oct 24, 2025
Novo Nordisk, Inc. vs. Mylan Pharmaceuticals Inc. | Robins Kaplan LLP - JDSupra
Novo Nordisk's patent infringement lawsuit against Mylan over Wegovy® (semaglutide) has been dismissed by a Delaware court. Mylan successfully argued it could not infringe the '003 patent as it does not administer drugs. The court also ruled in favor of Mylan regarding contributory and induced infringement claims, clarifying that Mylan's product label does not suggest administration without other therapeutic agents.
Oct 24, 2025
Developer of the popular weight-loss medication Mounjaro partners with Cipla to expand access in rural India.
Eli Lilly's weight-loss drug, Mounjaro, will be marketed in India as Yurpeak through a partnership with Cipla. This collaboration aims to expand access to tirzepatide, leveraging Cipla's distribution network. Mounjaro has quickly become a top-selling drug in India, outperforming Novo Nordisk's Wegovy. Experts view this partnership as a significant step in addressing the country's obesity crisis.
Oct 24, 2025
Dr. Reddy's Laboratories in India falls short of profit expectations due to intense competition in the US market for its generic cancer medication.
Dr Reddy's Laboratories reported a second-quarter profit of 13.47 billion rupees, falling short of estimates due to higher costs and competition for its generic cancer drug, lenalidomide, a version of Revlimid. Total revenue rose 9.8% to 88.28 billion rupees, driven by European demand for nicotine replacement therapy. The company faces challenges from delayed drug approvals and pricing pressures in North America.
Oct 24, 2025
Sanofi's $4 Billion Medication Sparks Surge, Yet Time Is Running Out - TradingView
Sanofi (SNY) reported strong earnings, driven by record sales of its eczema and asthma drug, Dupixent, which generated $4.16 billion. Despite a 5.2% stock jump, concerns loom as Dupixent's patent expires in 2031. The company is focusing on new therapies amid declining vaccine sales and ongoing discussions with the Trump administration on drug pricing.
Oct 23, 2025
Hengrui announces CLDN6 antibody-drug conjugates targeting ovarian cancer | BioWorld
Jiangsu Hengrui Pharmaceuticals Co. Ltd. has developed antibody-drug conjugates (ADCs) targeting claudin 6 (CLDN6) for the treatment of ovarian cancer. These ADCs link a CLDN6-targeting antibody to a cytotoxic drug, showing promise in cancer therapy.
Oct 23, 2025
Cipla, a major Indian pharmaceutical company, has signed an agreement to market Eli Lilly's weight-loss medication under a new brand name.
Cipla has secured distribution rights for Eli Lilly's weight-loss drug Mounjaro, rebranded as Yurpeak, in India. This strategic partnership aims to enhance access to tirzepatide, especially in underserved areas. Yurpeak will be priced competitively at ₹3,500 for the 2.5 mg dose. The collaboration follows previous ties on diabetic products and aligns with Cipla's efforts to expand its retail presence.
Oct 23, 2025
GSK's recently developed medication for multiple myeloma has received approval in the United States - The Times
The FDA has approved GSK's blood cancer drug, Blenrep, for adult patients with relapsed or refractory multiple myeloma, boosting the company's sales outlook. GSK anticipates Blenrep could achieve over £3 billion in peak sales, contributing to its goal of exceeding £40 billion in group sales by 2031, following a previous setback in July.
Oct 23, 2025
Cipla to market Eli Lilly's weight management medication under a different brand name in India - The Hindu
Eli Lilly has partnered with Cipla to market its weight-loss drug, Mounjaro, in India under the brand name Yurpeak. Lilly will manufacture the drug, while Cipla will handle marketing. Yurpeak will be available in six dose strengths and as a once-weekly injector pen, mirroring Mounjaro's format. The drug is part of the GLP-1 receptor agonist class.
Oct 23, 2025
Study: Cross-party backing for patent changes aimed at reducing medication costs | TechTarget
A new survey by the Initiative for Medicines, Access and Knowledge (I-MAK) reveals that 58% of Americans find prescription drug prices unreasonably high, with corporate greed cited as a major factor. The survey shows strong bipartisan support for patent reform and government regulations to limit drug prices, with 90% favoring easier access for generics and Medicare price negotiations.
Oct 23, 2025
Cipla to Market Eli Lilly's Weight-Loss Medication Under the Name Yurpeak in India - NDTV Profit
Eli Lilly's weight loss drug, Mounjaro, is now marketed in India as Yurpeak through a partnership with Cipla. The pre-filled injector pen will be available in six doses and is priced similarly to Mounjaro. Following its launch, Mounjaro became India's second-highest selling drug, reflecting a 42% sales increase in September amid rising demand for weight-loss therapies.
Oct 23, 2025
Roche's stock declines due to underwhelming sales of new medication - Global Banking | Finance | Review
Roche's shares fell 2.8% after disappointing sales of its eye disease drug Vabysmo and haemophilia treatment Hemlibra, despite a revenue rise to 45.9 billion Swiss francs. The company raised its earnings forecast but faces concerns over reliance on older drugs like Rituxan and Actemra. CEO Thomas Schinecker emphasized potential in the obesity drug market, currently dominated by Novo Nordisk and Eli Lilly.
Oct 23, 2025
Cipla to market Eli Lilly's weight-loss medication under the name Yurpeak in India - The Financial Express
Eli Lilly has partnered with Cipla to market its weight-loss drug, Mounjaro, in India under the brand name Yurpeak. The once-weekly pre-filled injector pen will be available in six dose strengths and priced similarly to Mounjaro. Lilly's Mounjaro sales have doubled since its launch in India for diabetes and obesity.
Oct 23, 2025
BCBSM attributes increasing insurance expenses to the pharmaceutical industry, but this claim is misguided. | Opinion - Detroit Free Press
In an op-ed, Blue Cross and Blue Shield of Michigan CEO Tricia Keith discussed rising healthcare costs but did not acknowledge the insurer's role in the issue. Stephen Rapundalo, CEO of MichBio, criticized Keith for overlooking Pharmacy Benefit Managers' impact on drug prices and suggested that all healthcare stakeholders must collaborate to reduce costs for patients.
Oct 23, 2025
Eli Lilly grants Cipla permission to market weight loss medication under a different brand name in India - The Economic Times
Oct 23, 2025
Eli Lilly grants Cipla permission to market weight loss medication under a different brand name in India - TradingView
Eli Lilly (LLY) has partnered with Cipla (CIPLA) to market its weight-loss drug, Mounjaro, in India under the brand name Yurpeak. Lilly will manufacture the drug, available in six dose strengths as a once-weekly injector pen. The agreement aims to enhance personalized treatment for patients, with pricing aligned to Mounjaro.
Oct 23, 2025
Roche patent lawsuit: Supreme Court declines to stop Natco's generic version of the spinal muscular atrophy medication Risdiplam.
The Supreme Court of India denied Roche's request for interim relief against Natco Pharma, which is producing a generic version of Roche's SMA treatment, Evrysdi, under the name Risdiplam. Roche claims patent infringement, but the Delhi High Court found the patent potentially invalid due to the compound's obviousness. The case will proceed to determine the patent's validity.
Oct 23, 2025
IPC to hold training sessions for public drug testing laboratories to assess contamination in cough syrups.
The Indian Pharmacopoeia Commission (IPC) will hold workshops in November for public drug testing labs across 10 states to address contamination issues in cough syrups. This initiative aims to enhance testing capabilities amid rising concerns over the safety of cough syrup products in the supply chain.
Oct 23, 2025
Radius Health, Inc. vs. Orbicular Pharmaceutical Technologies Private Limited | Robins Kaplan LLP - JDSupra
Radius Health, Inc. won a patent infringement case against Orbicular Pharmaceuticals regarding Tymlos® (abaloparatide), a drug for osteoporosis. The court upheld claims from three patents related to stable formulations, while finding two claims obvious. The ruling emphasized the uniqueness of abaloparatide's formulation and dismissed Orbicular's arguments on prior art.
Oct 23, 2025
Antidepressants Exhibit Significant Differences in Weight Gain, Heart Rate, and Blood Pressure Effects
A landmark study reveals significant variations in the effects of commonly prescribed antidepressants on weight, heart rate, and blood pressure, even with short-term use. Some medications can lead to clinically significant changes, including weight gain of up to 4 kg. The findings highlight the need for careful consideration when prescribing these drugs.
Oct 23, 2025
Research indicates that anti-obesity medications offer cardiovascular advantages in addition to aiding weight loss.
A new study funded by Novo Nordisk, which produces the anti-obesity drug semaglutide (Ozempic, Wegovy), reveals that the medication improves heart health regardless of weight loss. Patients experienced a 20% reduction in heart attacks and strokes, with benefits linked to waist circumference rather than overall weight. Researchers advocate for broader access to semaglutide while emphasizing the need to monitor side effects.
Oct 23, 2025
Cipla of India partners with Lilly to distribute the weight loss medication tirzepatide in the country - TradingView
Cipla has entered into an agreement with Eli Lilly to market tirzepatide, the active ingredient in the popular weight-loss drug Mounjaro, in India. This collaboration aims to expand access to the medication in the Indian market.
Oct 23, 2025
State Efforts Intensify to Lower Prices of Drug with Three Decades of Exclusive Rights
Starting January, Medicare will negotiate a lower price of approximately $30,000 annually for Enbrel, a drug used for autoimmune conditions. In 2027, Colorado will mandate this price under certain insurance plans, following a state panel's approval. Amgen, the manufacturer, is appealing a court decision that dismissed its lawsuit against the price cap.
Oct 23, 2025
Cipla to market the active component of the weight-loss medication Mounjaro in India | Khaleej Times
Cipla has entered into an agreement with Eli Lilly to market tirzepatide, the active ingredient in the popular weight-loss drug Mounjaro, in India. The collaboration aims to expand access to this medication in the Indian market.
Oct 23, 2025
Moderna announces that its CMV vaccine, previously anticipated to be a major success, did not meet expectations in a crucial trial.
Moderna's mRNA-1647 vaccine for cytomegalovirus (CMV) has failed a Phase 3 trial, achieving only 6% to 23% efficacy, prompting the company to halt further testing. CEO Stéphane Bancel expressed disappointment, noting the importance of CMV vaccine development. Despite the setback, Moderna does not anticipate changes to its financial forecasts but faces pressure to improve respiratory vaccine sales.
Oct 22, 2025
Strategies to reduce a medication's cost by 97 percent - Down To Earth
Recent rulings by the Delhi High Court and the Indian Patent Office have prioritized affordable medicines, revoking Novartis' patent on the cardiac drug Entresto (Vymada) for lacking novelty. This decision, supported by the Indian Pharmaceutical Alliance, paves the way for generics, potentially reducing prices by 70%. Additionally, Roche's patent on risdiplam faces challenges, with Natco offering a 97% price drop if successful.
Oct 22, 2025
Takeda Partners with China's Innovent to Create Cancer Treatments - Bloomberg.com
Innovent Biologics Inc. shares surged nearly 10% in Hong Kong after announcing a $1.2 billion deal with Takeda Pharmaceutical Co. to co-develop cancer drugs IBI363 and IBI343 for global markets, including the US. The agreement includes a $100 million equity investment from Takeda.
Oct 22, 2025
Takeda Enhances Its Pipeline and Revenue Potential Through $1.2 Billion Acquisition of Innovent's Cancer Medications
Takeda Pharmaceutical has invested $1.2 billion to acquire rights to two late-stage cancer drugs from Innovent Biologics, IBI363 and IBI343, aimed at treating solid tumors. This move is part of Takeda's strategy to offset revenue losses from expiring patents on its top-selling drug, Entyvio. The agreement also includes an option for an early-stage program, IBI3001.
Oct 22, 2025
Obesity Impairs Cancer Immunity: Could GLP-1 Medications Restore It?
Research at Duke University, led by Dr. Erika J. Crosby, suggests that obesity may weaken the immune system's response to breast cancer treatments. The study found that GLP-1 drugs like Ozempic can reverse this effect, improving cancer risk in obese mice. Crosby's work aims to explore how these medications could enhance cancer prevention strategies, particularly for women at risk.
Oct 22, 2025
Anti-Obesity Drugs Expected to Surge in Popularity by 2026 - Medscape
The pharmaceutical landscape for anti-obesity medications is evolving, with a surge in new drugs building on the success of GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound). Promising candidates, including retatrutide from Eli Lilly and MariTide from Amgen, are in late-stage trials, aiming for regulatory approval by 2026, potentially transforming obesity treatment and patient outcomes.
Oct 22, 2025
Tariff collection agency remains silent on plans for drug tariffs - Fort Wayne Business Weekly
U.S. Customs and Border Protection has declined to comment on President Trump's proposed 100% tariffs on imported patented drugs, set to begin Oct. 1, as negotiations with drug companies continue. The American Hospital Association warns that such tariffs could disrupt critical drug supplies, while industry experts argue that most prescriptions are for generics, limiting the tariffs' impact on consumers.
Oct 22, 2025
Concerns over medication costs drive initiatives for patent reform in the US - MLex
A new survey by the Initiative for Medicines, Access and Knowledge reveals strong bipartisan support among Americans for reforming US patent law to lower prescription drug prices. Vermont Senator Peter Welch advocates for limiting "patent thickets" to expedite the market entry of generic medications, reflecting public demand for legislative action on drug affordability.
Oct 22, 2025
Insights from a Court Victory Regarding India's Generic Drug Case - The Times of India
The Indian Supreme Court upheld a high court ruling favoring generic manufacturer Natco in its challenge against Roche's patent for Risdiplam, a life-saving drug for Spinal Muscular Atrophy (SMA). As a result, Risdiplam's price is set to drop from 600,000 to under 16,000 per bottle, highlighting the importance of utilizing TRIPS flexibilities in the pharmaceutical sector.
Oct 22, 2025
Calcutta High Court overturns the Indian Patent Office's rejection of Pharmacyclics' application.
On September 2, 2025, the Calcutta High Court overturned the Indian Patent Office's refusal of Pharmacyclics' patent application for a combination of ibrutinib and anti-CD20 antibodies, rituximab and ofatumumab. The court emphasized that divisional applications should be examined based on full specifications, reinforcing the interpretation of section 16 of the Patents Act.
Oct 21, 2025
ORPHAN Cures Act: $8.8 Billion Funding for… - Arnold Ventures
Mark E. Miller of Arnold Ventures criticized the CBO's updated analysis of the ORPHAN Cures Act, projecting an $8.8 billion cost to taxpayers over the next decade. The analysis highlights exemptions for cancer drugs like Keytruda, Opdivo, and Darzalex from Medicare price negotiations, which Miller argues protects pharmaceutical monopolies and contradicts efforts to lower drug prices.
Oct 21, 2025
Welch, Wyden, and Cortez Masto Propose Legislation to Prevent Republicans' Major Pharmaceutical Industry Bailout
Senators Peter Welch, Catherine Cortez Masto, and Ron Wyden introduced the No Big Blockbuster Bailouts Act (NOBBBA) to reverse Republican policies preventing Medicare from negotiating prices for blockbuster drugs. The Congressional Budget Office revealed a $8.8 billion bailout to Big Pharma, affecting drugs like Keytruda, Opdivo, and Darzalex. NOBBBA aims to lower costs for seniors and protect Medicare's negotiation authority.
Oct 21, 2025
Alligator Bioscience Receives US Patent for ATOR-4066 Bispecific Antibody
Alligator Bioscience has received US Patent No. 12,448,465 for ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, set to issue on October 21, 2025. This patent secures broad protection for ATOR-4066, which shows promising preclinical anti-tumor activity and is part of Alligator's immuno-oncology pipeline, alongside its lead drug, mitazalimab.
Oct 21, 2025
Cortez Masto, Welch, and Wyden Advocate for Senior Protection Against Republican Pharmaceutical Subsidies
U.S. Senators Catherine Cortez Masto, Peter Welch, and Ron Wyden introduced the No Big Blockbuster Bailouts Act to reverse provisions in a Republican tax law that prevent Medicare from negotiating prices for blockbuster drugs. The Congressional Budget Office revealed this policy resulted in an $8.8 billion bailout for Big Pharma, affecting drugs like Keytruda, Opdivo, and Darzalex.
Oct 21, 2025
The "Paper NDA" Issue: How the Division of Rico and Patent Claims Undermines Hatch...
In a patent case involving Janssen Products and PharmaMar's Yondelis® drug, the court denied their motion to amend the complaint to include fraud claims against EVER Valinject GmbH, which allegedly misappropriated confidential regulatory data. The court's bifurcation decision may complicate the legal process and risk patient safety, as it separates intertwined patent and fraud issues critical to determining the legitimacy of EVER's competing drug.
Oct 21, 2025
Janssen Pharmaceuticals, Inc. vs. Teva Pharmaceuticals USA, Inc. - Q3 2025 | Robins Kaplan LLP - JDSupra
The Federal Circuit upheld a ruling favoring Janssen Pharmaceuticals in a patent dispute over Invega Sustenna® (paliperidone palmitate). Teva Pharmaceuticals' appeal, claiming obviousness of the dosing regimen outlined in U.S. Patent No. 9,439,906, was rejected. The court found no motivation to combine prior art or reasonable expectation of success in developing the claimed treatment regimen.
Oct 21, 2025
TYH: Brand Name vs Generic Products - CKPG Today
Canadians are often faced with the choice between brand-name and generic drugs when filling prescriptions. While both contain the same active ingredients and function similarly, brand-name medications are generally more expensive due to the costs of research, testing, and marketing. Understanding these differences can help consumers make more informed decisions.
Oct 21, 2025
Celltrion announces unprecedented quarterly profit for Q3, achieving ₩1 trillion in sales driven by new cancer and immunology products.
Celltrion reported record third-quarter sales of 1.026 trillion won ($722 million) and an operating profit of 301.0 billion won, driven by strong demand for its biosimilars, including Remsima SC. New product launches, such as Stoboclo-Osenvelt and Omlyclo, contributed significantly to revenue. The company also acquired Eli Lilly’s New Jersey plant to enhance capacity and reduce tariff risks.
Oct 20, 2025
Research Indicates COVID Vaccines May Contribute to Increased Survival Rates in Cancer Patients - MedPage Today
A study presented at the ESMO congress revealed that non-small cell lung cancer (NSCLC) patients receiving mRNA COVID-19 vaccines around the time of immunotherapy had nearly double the 3-year survival rate compared to unvaccinated patients (55.8% vs 30.6%). The findings suggest that mRNA vaccines may enhance the effectiveness of PD-1 inhibitors like nivolumab (Opdivo) and pembrolizumab (Keytruda).
Oct 20, 2025
CBO Increases IRA Orphan Drug Exemption Cost Estimate by $3.9 Billion | InsideHealthPolicy.com
The Congressional Budget Office reports that exempting all orphan drugs from Medicare drug price negotiations could cost taxpayers $8.8 billion by 2034, a $3.9 billion increase from previous estimates. This adjustment reflects the inclusion of certain high-cost blockbuster drugs sold under Part B.
Oct 20, 2025
Novo Nordisk and D Young protect essential patent for semaglutide in tablet format.
Novo Nordisk's patent EP 3 746 111 B1, which enhances the bioavailability of semaglutide in tablet form, was upheld despite challenges regarding its inventive step. This decision marks a victory for Novo Nordisk, which faces ongoing patent disputes over semaglutide, used in its diabetes drug Ozempic and weight-loss injection Wegovy. Generic manufacturers continue to contest various patents at the European Patent Office.
Oct 20, 2025
Law Enforcement Disrupts Illegal Syrup Operations Nationwide in India, Confiscating Thousands of Bottles and Tablets
Authorities in India have dismantled illegal syrup networks, seizing over 23,000 bottles of banned codeine cough syrup and sedative tablets across Uttar Pradesh, Bihar, and Chhattisgarh. This coordinated effort highlights the ongoing battle against the illicit trade of narcotic-laced pharmaceuticals.
Oct 20, 2025
Global Industry Perspective and Capacity of the Generic Pharmaceuticals Market
The Insight Partners has released a report forecasting the Generic Drugs Market through 2031, analyzing key players like Teva Pharmaceutical Industries Ltd, Viatris Inc, and Novartis AG. The report highlights growth opportunities driven by product launches and acquisitions, while also addressing the impact of COVID-19 on market dynamics. It provides a comprehensive overview of market trends and regional segmentation.
Oct 20, 2025
Novo Nordisk's Overlooked Payment Leads to Premature Semaglutide Patent Expiration in Canada
Novo Nordisk A/S faces a significant setback after failing to maintain a key patent for semaglutide, the active ingredient in its weight-loss and diabetes drugs Ozempic and Wegovy. This oversight may allow generic competition, with Sandoz already seeking approval for a biosimilar in Canada. The lapse could cost Novo billions in revenue, highlighting the complexities of pharmaceutical patent management.
Oct 20, 2025
Senators Collins and Shaheen Bring Back Bipartisan Legislation Aimed at Reducing Prescription Drug Prices
U.S. Senators Susan Collins and Jeanne Shaheen have reintroduced the Ensuring Timely Access to Generics Act to enhance competition for generic drugs and lower prescription costs. The bipartisan legislation aims to improve oversight of the FDA's citizen petition process, preventing delays in generic drug approvals. This initiative seeks to reduce drug prices significantly for consumers.
Oct 20, 2025
Who encounters obstacles in obtaining GLP-1 prescriptions? - TechTarget
A study published in JAMA Health Forum reveals racial disparities in access to GLP-1 prescriptions, with 60.9% of White patients filling their prescriptions compared to 55.3% of Black and 58.4% of Hispanic patients. The average retail price for GLP-1 drugs exceeds $900 monthly, raising concerns about affordability and insurance coverage affecting access for minority groups.
Oct 20, 2025
Gwalior Ayurvedic Controversy: High Court Dismisses Request to Dismiss FIR Related to Counterfeit Medication
The Madhya Pradesh High Court has rejected a plea from M/s Madhavbaug Ayurvedic and Herbal Research Centre to quash an FIR related to the production of spurious Ayurvedic formulations. The court upheld the ongoing investigation into the adulterated drugs, reinforcing the enforcement of the Drugs and Cosmetics Act 1940.
Oct 20, 2025
Roche's Cancer Medication Receives FDA Approval, Introducing a New Biologic Treatment for Lupus Nephritis
Roche's Gazyva has received FDA approval to treat adults with active lupus nephritis, expanding its use beyond cancer. The drug, a monoclonal antibody targeting B cells, showed significant efficacy in a Phase 3 trial. This approval positions Gazyva as a competitor to GSK's Benlysta in the autoimmune market, with ongoing trials for further indications.
Oct 20, 2025
JOHN M. PIERCE: Trump Offered Big Pharma an Opportunity, But They Disrespected Him
President Trump has criticized Big Pharma for refusing to lower U.S. drug prices to match those in other countries, despite his threats of enforcement action. The industry, represented by PhRMA, has not complied, prompting calls for the DOJ and FTC to pursue antitrust actions against companies using tactics to maintain high prices. Americans deserve fair pricing for medications.
Oct 20, 2025
Important Intellectual Property Licensing Factors for AI-Driven Drug Discovery Platforms | JD Supra
AI is revolutionizing drug discovery, enabling faster target identification and lead optimization. Companies like Company A are leveraging AI platforms for licensing deals, while Pharma Company B seeks to license compounds for an oncology indication. Key considerations include patent ownership, data management, and regulatory compliance, as the landscape of AI in biotech evolves.
Oct 19, 2025
AstraZeneca's Datroway improves survival rates in advanced breast cancer cases - KFGO
AstraZeneca and Daiichi Sankyo's breast cancer drug, Datroway, has shown significant survival benefits in a late-stage trial for triple-negative breast cancer, with a median overall survival of 23.7 months compared to 18.7 months for chemotherapy. The drug, an antibody-drug conjugate, received U.S. approval earlier this year and may compete with Gilead's Trodelvy.
Oct 19, 2025
BioCryst's $700 million acquisition of Astria positions the company to compete more effectively against bigger players in the rare disease HAE market.
BioCryst Pharmaceuticals has announced a $700 million acquisition of Astria Therapeutics to enhance treatment options for hereditary angioedema (HAE) patients. Astria's lead drug, navenibart, aims to reduce injection frequency to as few as two shots per year. BioCryst's current HAE treatment, Orladeyo, generated $437.6 million in sales last year, with projections for significant revenue growth by 2029.
Oct 19, 2025
India creates its first homegrown antibiotic, according to DrugsControl Media Services.
India has achieved a significant milestone by developing Nafithromycin, its first indigenous antibiotic. This breakthrough underscores the country's commitment to self-reliance in the pharmaceutical and biotechnology sectors, particularly in combating antibiotic resistance.
Oct 19, 2025
NCB Conducts Raid on Unlawful Alprazolam Manufacturing Facility in Ratlam, Leading to Arrest of Two Individuals and Seizure of ₹3.44 Crore
The Narcotics Control Bureau's Indore Zonal Unit has raided an illegal Alprazolam factory in Ratlam, Madhya Pradesh, leading to the arrest of two individuals and the seizure of contraband worth ₹3.44 crore. This operation highlights ongoing efforts to combat illicit drug manufacturing in the region.
Oct 19, 2025
MP SIT issues notice to Tamil Nadu's drug regulatory authority regarding cough syrup, according to DrugsControl Media Services.
The Madhya Pradesh SIT investigating cough syrup deaths in Chhindwara and Betul has requested the Tamil Nadu government's food safety and drug administration department to provide inspection, audit, and compliance records for Sresan Pharmaceuticals.
